Clinical Trial Update: A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab [Phase 1]

View source ↗

Summary

Phase 1 study of DKN-01 with paclitaxel or pembrolizumab in esophageal and gastroesophageal cancers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma
• Esophagogastric Junction Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• DKN-01 (dkn-01)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Leap Therapeutics, Inc. | Conditions: Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Status: COMPLETED